Matches in SemOpenAlex for { <https://semopenalex.org/work/W4313350032> ?p ?o ?g. }
Showing items 1 to 86 of
86
with 100 items per page.
- W4313350032 endingPage "74.1" @default.
- W4313350032 startingPage "74.1" @default.
- W4313350032 abstract "Abstract Targeted monoclonal antibodies (mAb) can be used therapeutically for tumors with identifiable antigens such as disialoganglioside GD2, expressed on neuroblastoma and melanoma. αGD2 mAbs have been clinically successful in patients with neuroblastoma. An important mechanism of mAb therapy is Antibody Dependent Cellular Cytotoxicity (ADCC). Combinatorial therapeutic strategies can dramatically increase the anti-tumor response elicited by mAbs. We combined a novel αGD2 mAb, hu14.18K322A, with an immunostimulatory regimen of agonist CD40 mAb and class B CpG-ODN 1826. This combination immunotherapy produced a synergistic anti-tumor response in a syngeneic model of melanoma with minimal tumor burden, resulting in long-term cure of mice. NK depletion in B6 mice showed NK cells were required for the anti-tumor effect. Anti-tumor responses were also observed in tumor-bearing SCID/beige mice; thus NK cell cytotoxicity was not essential. Interrogation of the myeloid population in the peritoneal cavity showed an increase in neutrophils and monocytes with high Fc receptor expression after treatment with αCD40 +CpG. Furthermore, plastic adherent peritoneal cells inhibited tumor cells in vitro in an antibody-dependent manner. These data highlight the importance of myeloid cells as potential effectors in immunotherapy regimens utilizing tumor-specific mAb and suggest further studies are needed to investigate the therapeutic potential of activated myeloid cells." @default.
- W4313350032 created "2023-01-06" @default.
- W4313350032 creator A5000263428 @default.
- W4313350032 creator A5010708307 @default.
- W4313350032 creator A5011569932 @default.
- W4313350032 creator A5030792508 @default.
- W4313350032 creator A5042234824 @default.
- W4313350032 creator A5045180889 @default.
- W4313350032 creator A5091594218 @default.
- W4313350032 date "2012-05-01" @default.
- W4313350032 modified "2023-10-01" @default.
- W4313350032 title "Increased anti-melanoma efficacy of hu14.18K322A by combining with αCD40 +CpG (74.1)" @default.
- W4313350032 doi "https://doi.org/10.4049/jimmunol.188.supp.74.1" @default.
- W4313350032 hasPublicationYear "2012" @default.
- W4313350032 type Work @default.
- W4313350032 citedByCount "0" @default.
- W4313350032 crossrefType "journal-article" @default.
- W4313350032 hasAuthorship W4313350032A5000263428 @default.
- W4313350032 hasAuthorship W4313350032A5010708307 @default.
- W4313350032 hasAuthorship W4313350032A5011569932 @default.
- W4313350032 hasAuthorship W4313350032A5030792508 @default.
- W4313350032 hasAuthorship W4313350032A5042234824 @default.
- W4313350032 hasAuthorship W4313350032A5045180889 @default.
- W4313350032 hasAuthorship W4313350032A5091594218 @default.
- W4313350032 hasConcept C104317684 @default.
- W4313350032 hasConcept C109316439 @default.
- W4313350032 hasConcept C147483822 @default.
- W4313350032 hasConcept C150194340 @default.
- W4313350032 hasConcept C154317977 @default.
- W4313350032 hasConcept C159654299 @default.
- W4313350032 hasConcept C190727270 @default.
- W4313350032 hasConcept C202751555 @default.
- W4313350032 hasConcept C203014093 @default.
- W4313350032 hasConcept C22801619 @default.
- W4313350032 hasConcept C2777658100 @default.
- W4313350032 hasConcept C2777701055 @default.
- W4313350032 hasConcept C2779282312 @default.
- W4313350032 hasConcept C39347974 @default.
- W4313350032 hasConcept C40677261 @default.
- W4313350032 hasConcept C502942594 @default.
- W4313350032 hasConcept C542903549 @default.
- W4313350032 hasConcept C55493867 @default.
- W4313350032 hasConcept C71924100 @default.
- W4313350032 hasConcept C86803240 @default.
- W4313350032 hasConcept C8891405 @default.
- W4313350032 hasConceptScore W4313350032C104317684 @default.
- W4313350032 hasConceptScore W4313350032C109316439 @default.
- W4313350032 hasConceptScore W4313350032C147483822 @default.
- W4313350032 hasConceptScore W4313350032C150194340 @default.
- W4313350032 hasConceptScore W4313350032C154317977 @default.
- W4313350032 hasConceptScore W4313350032C159654299 @default.
- W4313350032 hasConceptScore W4313350032C190727270 @default.
- W4313350032 hasConceptScore W4313350032C202751555 @default.
- W4313350032 hasConceptScore W4313350032C203014093 @default.
- W4313350032 hasConceptScore W4313350032C22801619 @default.
- W4313350032 hasConceptScore W4313350032C2777658100 @default.
- W4313350032 hasConceptScore W4313350032C2777701055 @default.
- W4313350032 hasConceptScore W4313350032C2779282312 @default.
- W4313350032 hasConceptScore W4313350032C39347974 @default.
- W4313350032 hasConceptScore W4313350032C40677261 @default.
- W4313350032 hasConceptScore W4313350032C502942594 @default.
- W4313350032 hasConceptScore W4313350032C542903549 @default.
- W4313350032 hasConceptScore W4313350032C55493867 @default.
- W4313350032 hasConceptScore W4313350032C71924100 @default.
- W4313350032 hasConceptScore W4313350032C86803240 @default.
- W4313350032 hasConceptScore W4313350032C8891405 @default.
- W4313350032 hasIssue "1_Supplement" @default.
- W4313350032 hasLocation W43133500321 @default.
- W4313350032 hasOpenAccess W4313350032 @default.
- W4313350032 hasPrimaryLocation W43133500321 @default.
- W4313350032 hasRelatedWork W2029145496 @default.
- W4313350032 hasRelatedWork W2061223989 @default.
- W4313350032 hasRelatedWork W2067077431 @default.
- W4313350032 hasRelatedWork W2116591654 @default.
- W4313350032 hasRelatedWork W2122584026 @default.
- W4313350032 hasRelatedWork W2122854061 @default.
- W4313350032 hasRelatedWork W2328036837 @default.
- W4313350032 hasRelatedWork W2443772760 @default.
- W4313350032 hasRelatedWork W2476973230 @default.
- W4313350032 hasRelatedWork W339756260 @default.
- W4313350032 hasVolume "188" @default.
- W4313350032 isParatext "false" @default.
- W4313350032 isRetracted "false" @default.
- W4313350032 workType "article" @default.